Acelyrin, Inc. (SLRN)

Market Cap	1.62B
Revenue (ttm)	n/a
Net Income (ttm)	-64.77M
Shares Out	92.70M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	428,563
Open	18.15
Previous Close	17.85
Day's Range	16.84 - 18.22
52-Week Range	16.84 - 25.84
Beta	n/a
Analysts	Strong Buy
Price Target	42.67 (+143.83%)
Earnings Date	Jun 13, 2023

About SLRN

ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. We are driven by our sense of urgency to bring life-changing therapies to patients globally, a core value that we refer to as “courageous caring.” Our initial focus is on the treatment of diseases with pathology related to excess activation of the immune system, an area where our management and team bring industry-leading expertise. We acquired our portfolio of product candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2023
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: SLRN

Analyst Forecast

According to 4 analysts, the average rating for SLRN stock is "Strong Buy." The 12-month stock price forecast is $42.67, which is an increase of 143.83% from the latest price.

Price Target

$42.67

(143.83% upside)

Analyst Consensus: Strong Buy